Valeur202020212022202320242025TTMFrais de vente, généraux et administratifs528.93 M619.92 M665.1 M747.86 M751 M743.07 M724.7 MRecherche et développement———————Résultat d'exploitation432.73 M589.86 M650.98 M617.26 M227.35 M25.16 M70.39 MTotal des produits hors exploitation197.55 M-60.87 M30.12 M97.58 M-12.92 M-22.02 M-134.31 MCharges d'intérêts, nettes des intérêts capitalisés86.43 M73.91 M59.29 M136.71 M126.29 M107.03 M105.89 MRésultat hors exploitation, hors charges d'intérêts11.13 M-98.89 M-59.69 M-134.67 M-122.69 M-106.48 M-105.71 MRevenus/dépenses exceptionnels99.98 M-35.89 M30.52 M95.54 M-16.52 M-22.58 M-134.5 MRésultat avant impôts447.11 M480.71 M622.99 M581.28 M93.11 M-99.5 M29.17 MPart des actionnaires dans le résultat-27.6 M-40.2 M—————Impôts81.81 M81.87 M130.38 M100.91 M67.82 M42.66 M17.42 MIntérêts ne donnant pas le contrôle / intérêts minoritaires1 M7.86 M6.38 M5.75 M3.09 M2.17 M1.81 MAutres produits/charges après impôts-17.27 M-4.96 M-27.54 M-1.59 M-33.25 M-2.5 M35.9 MRésultat net avant activités abandonnées364.3 M390.98 M486.23 M474.62 M22.2 M-144.34 M-184.65 MActivités abandonnées0——————Résultat net364.3 M390.98 M486.23 M474.62 M22.2 M-144.34 M-184.65 MAjustement de dilution——00———Dividendes privilégiés——3.52 M-3.32 M———Résultat net dilué revenant aux actionnaires ordinaires364.3 M390.98 M482.7 M477.94 M10.3 M-144.34 M-184.65 MBénéfice par action de base (BPA de base)7.357.779.579.270.2-2.91-3.71Bénéfice par action dilué (BPA dilué)7.27.69.489.220.2-2.91-3.71Nombre moyen d'actions de base en circulation49.55 M50.29 M50.81 M51.23 M51.38 M49.56 M—Nombre d'actions en circulation après dilution50.61 M51.42 M51.3 M51.45 M51.63 M49.56 M—EBITDA2.5 B3.09 B3.63 B3.56 B3.15 B2.79 B2.5 BEBIT2.26 B2.83 B3.33 B3.24 B2.79 B2.39 B2.15 BCoût des ventes————46.99 M12.44 M7.17 MAutres coûts des ventes————46.99 M12.44 M7.17 MAmortissements (flux de trésorerie)234.92 M265.54 M303.87 M314.12 M361.74 M403.31 M350.1 M
Charles River Laboratories International, Inc. Common Stock
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration. The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.